Xadovild M 500mg/50mg Tablet is a combination oral antidiabetic medication containing Metformin 500mg and Vildagliptin 50mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by increasing the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The synergistic action of these agents helps in achieving better glycemic control compared to monotherapy, reducing fasting and postprandial blood glucose levels. Xadovild M is typically prescribed as an adjunct to diet and exercise in patients inadequately controlled on either component alone or when combination therapy is deemed appropriate. It is important to monitor renal function prior to and during treatment, as Metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Vildagliptin is generally well tolerated but may rarely cause hypersensitivity reactions. Regular blood glucose monitoring and adherence to prescribed lifestyle modifications enhance therapeutic outcomes with Xadovild M.